A SMAP in the face for cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Deficits in protein phosphatase 2A (PP2A) function are implicated in various human cancers.
• Restoring PP2A activity is a therapeutic strategy to inhibit tumor progression.

Purpose of the Study:

• To characterize novel, orally available small molecule activators of PP2A (SMAPs).
• To evaluate the efficacy of SMAPs in preclinical cancer models, particularly KRAS-mutant lung cancer.

Main Methods:

• Characterization of SMAP compounds.
• Assessment of SMAP effects on mitogenic signaling and apoptosis in cancer cell lines.
• Evaluation of tumor growth inhibition in murine models.
• Analysis of resistance mechanisms related to PP2A A subunit mutations.

Main Results:

• SMAPs were identified as orally available compounds that activate PP2A.
• SMAPs attenuated mitogenic signaling and induced apoptosis in KRAS-mutant lung cancer cells.
• SMAPs inhibited tumor growth in relevant preclinical models.
• Tumor resistance to SMAPs was observed in the presence of specific mutations in the PP2A A subunit.

Conclusions:

• SMAPs represent a promising class of potential anticancer therapeutics.
• Further research into PP2A-regulated pathways targeted by SMAPs is crucial for optimizing cancer treatment strategies.
• Identifying specific cancer types most responsive to SMAPs will guide clinical application.